Diagnostic utility of the paracetamol concentration aminotransferase activity multiplication product in identifying patients exceeding the 150 mg/L treatment line on the Rumack–Matthew nomogram
4
Issued Date
2025-01-01
Resource Type
ISSN
15563650
eISSN
15569519
Scopus ID
2-s2.0-105024661024
Pubmed ID
41378892
Journal Title
Clinical Toxicology
Rights Holder(s)
SCOPUS
Bibliographic Citation
Clinical Toxicology (2025)
Suggested Citation
Chomchai S., Mekavuthikul P., Phuditshinnapatra J., Chomchai C. Diagnostic utility of the paracetamol concentration aminotransferase activity multiplication product in identifying patients exceeding the 150 mg/L treatment line on the Rumack–Matthew nomogram. Clinical Toxicology (2025). doi:10.1080/15563650.2025.2579132 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/113625
Title
Diagnostic utility of the paracetamol concentration aminotransferase activity multiplication product in identifying patients exceeding the 150 mg/L treatment line on the Rumack–Matthew nomogram
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: Paracetamol poisoning and the associated liver damage can be effectively managed by the timely administration of acetylcysteine. Most treatment protocols depend on the line intersecting 150 mg/L (992 μmol/L) at 4 h on the Rumack–Matthew nomogram (150-treatment line), which requires accurate determination of ingestion time to assess risk. The paracetamol concentration aminotransferase activity multiplication product has emerged as a predictive measure for paracetamol-induced hepatotoxicity in patients receiving acetylcysteine, without necessitating the precise knowledge of ingestion time. This study aims to assess the diagnostic performance of the multiplication product in identifying cases with paracetamol concentrations surpassing the 150-treatment line and to establish an optimal cutoff value for this clinical tool. Methods: A retrospective review of acute paracetamol overdoses admitted to Siriraj Hospital in Bangkok, Thailand, from January 2007 to December 2016 was conducted. The multiplication product was calculated by multiplying the serum paracetamol concentration (mg/L) by the higher activity of alanine aminotransferase or aspartate aminotransferase (U/L), both measured from simultaneous blood samples. The diagnostic accuracy of the multiplication product in predicting paracetamol concentrations above the 150-treatment line was evaluated through receiver operating characteristic curve analysis, sensitivity, and specificity. The optimal cutoff value was determined using the Youden index. Results: Among the 934 patients included, 43.5% (406 cases) presented paracetamol concentrations above the 150-treatment line. The multiplication product had an area under the receiver operating characteristic curve of 0.874. An optimal cutoff of 1,501.6 mg * U/L<sup>2</sup> yielded a sensitivity of 84.8% and a specificity of 79.8%. Discussion: The 150-treatment line on the Rumack–Matthew nomogram demonstrated a sensitivity of 100.0% (95% CI: 93.7 − 100.0%) and a specificity of 60.2% (95% CI: 56.9 − 63.5%) for predicting hepatotoxicity. In comparison, the 1,500 mg * U/L<sup>2</sup> cutoff of the paracetamol concentration aminotransferase activity multiplication product showed a sensitivity of 98.3% (95% CI: 90.6 − 100.0%) and a specificity of 50.7% (95% CI: 47.4 − 54.1%). Conclusions: The paracetamol concentration aminotransferase activity multiplication product demonstrates predictive ability for serum paracetamol concentrations at or above the 150-treatment line on the Rumack–Matthew nomogram.